Mechanisms Underlying Insulin Deficiency-Induced Acceleration of β-Amyloidosis in a Mouse Model of Alzheimer’s Disease

Latha Devi1, Melissa J. Alldred1, Stephen D. Ginsberg1,2,3, Masuo Ohno1,2

1 Center for Dementia Research, Nathan Kline Institute, Orangeburg, New York, United States of America, 2 Department of Psychiatry, New York University Langone Medical Center, New York, New York, United States of America, 3 Department of Physiology and Neuroscience, New York University Langone Medical Center, New York, New York, United States of America

Abstract

Although evidence is accumulating that diabetes mellitus is an important risk factor for sporadic Alzheimer’s disease (AD), the mechanisms by which defects in insulin signaling may lead to the acceleration of AD progression remain unclear. In this study, we applied streptozotocin (STZ) to induce experimental diabetes in AD transgenic mice (5XFAD model) and investigated how insulin deficiency affects the β-amyloidogenic processing of amyloid precursor protein (APP). Two and half months after 5XFAD mice were treated with STZ (90 mg/kg, i.p., once daily for two consecutive days), they showed significant reductions in brain insulin levels without changes in insulin receptor expression. Concentrations of cerebral amyloid-β peptides (Aβ40 and Aβ42) were significantly increased in STZ-treated 5XFAD mice as compared with vehicle-treated 5XFAD controls. Importantly, STZ-induced insulin deficiency upregulated levels of both β-site APP cleaving enzyme 1 (BACE1) and full-length APP in 5XFAD mouse brains, which was accompanied by dramatic elevations in the β-cleaved C-terminal fragment (C99). Interestingly, BACE1 mRNA levels were not affected, whereas phosphorylation of the translation initiation factor eIF2α, a mechanism proposed to mediate the post-transcriptional upregulation of BACE1, was significantly elevated in STZ-treated 5XFAD mice. Meanwhile, levels of GGA3, an adapter protein responsible for sorting BACE1 to lysosomal degradation, are indistinguishable between STZ- and vehicle-treated 5XFAD mice. Moreover, STZ treatments did not affect levels of Aβ-degrading enzymes such as neprilysin and insulin-degrading enzyme (IDE) in 5XFAD brains. Taken together, our findings provide a mechanistic foundation for a link between diabetes and AD by demonstrating that insulin deficiency may change APP processing to favor β-amyloidogenesis via the translational upregulation of BACE1 in combination with elevations in its substrate, APP.

Introduction

Alzheimer’s disease (AD) is a devastating neurodegenerative disorder and the most common form of dementia among the elderly population. Although the cause of AD in sporadic forms has not been completely determined, there is increasing consensus that accumulation of the amyloid-β (Aβ) peptide plays a central role in triggering a cascade ultimately leading to profound neuronal death and memory defects [1,2]. Importantly, a number of risk factors have been identified that may shed light on the molecular mechanisms underlying the development of sporadic AD; in particular, recent evidence suggests a close relationship between sporadic AD and diabetes mellitus [3–5]. Consistent with the observation that patients with type 2 diabetes characterized by insulin resistance are at an increased risk of getting AD, not only reductions in insulin levels and insulin receptor expression but also deficient downstream signaling pathways have been reported to occur in brains of AD patients [6–9]. Furthermore, clinical data are available on the association between AD and type 1 diabetes resulting from hypoinsulinemia [10]. Therefore, it seems reasonable to hypothesize that sporadic AD represents a form of diabetes that selectively involves the brain and has the disturbed insulin signaling pathway in common with type 1 and type 2 diabetes mellitus [11]. This hypothesis is supported by recent findings that analogue compounds for the incretin hormone glucagon-like peptide-1 (GLP-1), which facilitate endogenous insulin release and are used to treat type 2 diabetes, reduce Aβ accumulation and rescue impairments in hippocampal synaptic plasticity and spatial learning and memory in transgenic mouse models of AD [12–14]. In a clinical setting, treatments with insulin in combination with other antidiabetic medication are shown to lower plaque load and benefit cognitive function in AD patients with diabetes [15,16]. Moreover, it has been demonstrated that soluble Aβ oligomers produce a loss of neuronal surface insulin receptors and directly interfere with the insulin signaling pathway [17–20].

To further investigate an association between neuronal insulin dysfunction and Aβ accumulation in AD, streptozotocin (STZ), an agent that selectively destroys insulin-secreting pancreatic β cells
and thereby causes insulin depletion, has been applied to AD transgenic mice overexpressing human amyloid precursor protein (APP) [5]. Interestingly, these studies have revealed that STZ-induced cerebral insulin deficiency in APP transgenic mice exacerbates the development of AD-like phenotypes such as β-amyloidosis and memory impairments [21–23]. Taken collectively, different lines of experimental data suggest a link between diabetes and AD in the pathogenesis of disease; however, the underlying mechanism is poorly understood.

In this study, we investigated the mechanisms by which insulin deficiency may accelerate AD progression in the 5XFAD transgenic mouse model. 5XFAD mice co-overexpress human APP and presenilin 1 (PS1) harboring five familial AD (FAD) mutations [24–26]. 5XFAD mice begin to develop visible amyloid deposition as early as 2 months of age and exhibit memory declines on hippocampus-dependent behavioral tasks between 4–6 months concomitant with moderate Aβ accumulation and impaired synaptic physiology at Schaffer collateral-CA1 pathways [24,25,27–29]. For our study, STZ was administered to young 5XFAD mice (1.5 months old) that have not yet developed amyloid pathology, and we compared levels of key molecules involved in β-amyloidosis between STZ- and vehicle-treated subjects at 4 months of age. The molecules tested include β-site APP cleaving enzyme 1 (BACE1), a disintegrin and metalloproteinase 10 (ADAM10) and PS1 responsible for the processing of APP, full-length APP, its β- and α-cleavage products, and Aβ-degrading enzymes such as neprilysin and insulin-degrading enzyme (IDE). We demonstrate that insulin deficiency facilitates cerebral β-amyloidogenesis in 5XFAD mouse brains accompanied by significant elevations in BACE1 and APP expression in the absence of changes in levels of β-, γ-secretase or Aβ-degrading enzymes. The results also suggest that translational mechanisms through phosphorylation of eukaryotic initiation factor-2α may underlie the upregulation of BACE1 associated with insulin-deficient diabetes.

Results

Insulin deficiency facilitates Aβ accumulation in 5XFAD mice

To examine the effects of insulin deficiency on β-amyloidosis, 5XFAD mice at 1.5 months of age were administered with STZ (90 mg/kg, i.p.) once daily for two consecutive days after overnight fast. Two and half months later, hemibrain samples were collected from STZ- and saline vehicle-treated subjects. First, immunoblot analysis of brain homogenates demonstrated that insulin levels were significantly reduced in STZ-treated 5XFAD mice compared with saline-treated 5XFAD controls ($F(1,9) = 7.98, p<0.05$), while STZ treatments did not affect insulin receptor expression (Fig. 1A, B). Next, sandwich ELISAs were performed to compare Aβ levels in STZ- and vehicle-treated 5XFAD mice (Fig. 1C). Consistent with previous findings [21–23], STZ-induced insulin deficiency significantly increased cerebral levels of Aβ40 ($F(1,7) = 7.49, p<0.05$) and Aβ42 ($F(1,6) = 8.56, p<0.05$) in 5XFAD mice.

Insulin deficiency elevates BACE1 and full-length APP in 5XFAD mice

To address the mechanisms underlying the acceleration of Aβ accumulation in STZ-induced diabetic 5XFAD mouse brains, we first investigated changes in the β-amyloidogenic processing of APP (Fig. 2). Immunoblot analysis demonstrated that STZ-induced insulin deficiency elevated levels of the β-secretase BACE1 in 5XFAD mice (Fig. 2A). Quantitative analysis revealed that BACE1 expression in brains of STZ-treated 5XFAD mice was significantly higher than that of vehicle-treated 5XFAD mice ($F(1,9) = 9.49, p<0.05$) (Fig. 2B). It should be noted that baseline levels of BACE1 in vehicle-treated groups were indistinguishable between 5XFAD and wild-type control mice at 4 months of age (data not shown), although BACE1 expression increases with age (≥6 months) in 5XFAD mouse brains [30,31]. Meanwhile, STZ treatments did not significantly affect levels of ADAM10 and PS1 associated with β- and γ-secretase activities, respectively, in 5XFAD mice (Fig. 2B). Therefore, the change was specific to β-secretase in insulin-deficient 5XFAD mice.
In addition to increases in BACE1 expression, STZ treatments also significantly elevated levels of full-length APP, a substrate of BACE1, in 5XFAD mice ($F(1,9) = 10.66, p < 0.05$) (Fig. 2C). Consistent with these changes, levels of the β-cleaved C-terminal fragment of APP (C99) were dramatically elevated ($F(1,9) = 21.73, p < 0.05$), while levels of the secreted ectodomain of APP formed by α-secretase cleavage (sAPPα) were significantly reduced ($F(1,9) = 51.26, p < 0.05$) in STZ-treated 5XFAD mouse brains (Fig. 2C). Together, these data indicate that STZ-induced insulin deficiency alters APP processing to promote the β-amyloidogenic pathway through the upregulation of BACE1 and APP expression.

Mechanisms by which insulin deficiency elevates BACE1 in 5XFAD mice

We next investigated whether transcriptional and/or post-transcriptional mechanisms may underlie the BACE1 elevation found in STZ-induced diabetic 5XFAD mice (Fig. 3). qPCR analysis of brain homogenates revealed that BACE1 mRNA levels were not significantly different between STZ- and vehicle-treated 5XFAD mice (Fig. 3A). Recent studies including our analysis have shown that phosphorylation of the translation initiation factor eIF2α (phospho-eIF2α) plays an important role in mediating the post-transcriptional upregulation of BACE1 in sporadic AD and 5XFAD mice at advanced stages of disease with massive amyloid pathology [31–33]. Therefore, we tested the possibility that the phospho-eIF2α pathway may be involved in the upregulation of BACE1 in STZ-treated 5XFAD mice (Fig. 3B). In parallel with elevations in BACE1 expression, STZ-induced insulin deficiency resulted in significant increases in phospho-eIF2α levels ($F(1,9) = 18.78, p < 0.05$) without affecting total eIF2α levels in 5XFAD mouse brains (Fig. 3C). Moreover, we found that STZ treatments activated PKR-endoplasmic reticulum-related kinase (PERK: an eIF2α kinase) in 5XFAD mouse brains, as measured by a dramatic increase in a phosphorylated form of PERK (phospho-eIF2α) in STZ-treated 5XFAD mouse brains ($F(1,9) = 4.97, p = 0.05$) (Fig. 3D). Therefore, the results suggest that translational mechanisms through activation of the eIF2α phosphorylation pathway rather than transcriptional mechanisms may account for the elevation of BACE1 expression in brains of STZ-induced diabetic 5XFAD mice.

We further examined whether changes in the BACE1-degrading pathway may be involved in the BACE1 elevation in STZ-treated 5XFAD mouse brains (Fig. 3E). Recent evidence indicates that BACE1 protein stability can be modulated by the lysosomal degradation pathway; in particular, caspase-3-dependent cleavage of Golgi-localized γ-ear-containing ARF-binding protein 3 (GGA3) is proposed to reduce BACE1 trafficking to the lysosome and thereby cause BACE1 elevation in AD [34–37]. In this study, STZ treatments did not induce caspase-3 activation as assessed by increases in its 17-kDa fragments or reductions in GGA3 levels in 5XFAD mice (Fig. 3F). Therefore, it is unlikely that alteration of the GGA3-mediated BACE1 degradation mechanism may underlie the upregulation of BACE1 associated with insulin deficiency in 5XFAD mice.
Insulin deficiency does not affect neprilysin or IDE levels in 5XFAD mice

In addition to the facilitation of β-amyloidogenesis through BACE1 and APP elevations, it is possible that changes in the Aβ metabolism may also contribute to increases in Aβ40 and Aβ42 levels in STZ-treated 5XFAD mice. Therefore, we examined whether STZ treatments may affect neprilysin and/or IDE, key enzymes responsible for the degradation and clearance of Aβ peptides [38,39], in 5XFAD mice (Fig. 4A). However, levels of neprilysin and IDE were indistinguishable between STZ- and vehicle-treated 5XFAD mouse brains (Fig. 4B), suggesting that increased levels of Aβ accumulation in insulin-deficient diabetic 5XFAD mice do not result from alterations in these Aβ-degrading enzymes.

Discussion

Consistent with epidemiological investigations showing that diabetes is an important risk factor for sporadic AD, a growing body of evidence indicates defective insulin signaling in AD brains [6–9]. In this study, insulin deficiency evoked by STZ administration in the pre-pathological stage of 5XFAD mice (1.5 months of age) accelerated the subsequent Aβ accumulation in brain, suggesting that insulin dysfunction may not only be a consequence of AD pathology but also play a causal role in triggering the disease process. In other transgenic mouse models of AD, STZ-induced cerebral insulin depletion has also been reported to aggravate AD-like traits such as amyloid plaques, tau phospho-
mice, which show modest Aβ baseline levels of BACE1 in vehicle-treated 5XFAD mice. Sporadic AD and advanced pathological phases of 5XFAD mice represent an important molecular mechanism by which diabetes with insulin-deficient diabetes may not account for the BACE1 elevation associated with diabetes. It has been reported that increases in phosphorylated eIF2α may downregulate eIF2α kinase and/or upregulate eIF2α2 phosphorylation in STZ-treated 5XFAD mice. This is consistent with the observation showing that mRNA and protein levels of PERK are significantly upregulated in STZ-injected rats [42]. Moreover, expression of dominant-negative PERK is shown to block energy deprivation-induced increases of both eIF2α phosphorylation and BACE1 in HEK293 cell line cultures [33]. Although further study is required for the demonstration of a causal link, the present data suggest that the PERK-eIF2α phosphorylation pathway may, at least in part, play a role in mediating the BACE1 elevation associated with deficient insulin signaling in diabetic 5XFAD mice.

Are transcriptional or translational mechanisms responsible for increases in protein and activity levels of BACE1 in sporadic AD brains [43-45]? Some studies with postmortem human brains report elevations in BACE1 mRNA levels associated with sporadic AD [46,47], while others show no changes in mRNA despite the increased levels of BACE1 activity and protein [48-51]. Interestingly, our previous study demonstrated that behavioral stress elevates BACE1 protein levels concomitant with increases in both BACE1 mRNA and a phosphorylated form of eIF2α in 5XFAD mice [52]. BACE1 expression is upregulated without increases in mRNA levels in the diabetic 5XFAD model in this study. Although further investigation is needed, it is interesting to argue that differences in environmental factors, which predominantly contribute to disease progression, may determine whether the transcriptional and/or translational mechanisms underlie BACE1 elevations in sporadic AD. With regard to BACE1 stability, GGA3 has been proposed to play a crucial role in the transport of ubiquitinated BACE1 to the lysosomal degradation [34,36]. GGA3 is a substrate for caspase-3 cleavage; therefore, under apoptotic conditions, GGA3 inactivation by caspase-3 leads to increased BACE1 protein stability [34,35]. Importantly, GGA3 levels are significantly decreased in AD brains and inversely correlate with increased levels of BACE1 expression [34,37]. However, the absence of caspase-3 activation and GGA3 reduction in our STZ-treated 5XFAD model indicates that the mechanism of BACE1 elevation associated with diabetic insulin deficiency is distinct from mechanisms mediated by depletion of the BACE1-sorting protein GGA3 during apoptosis.

In addition to BACE1 elevations, levels of the substrate APP were also upregulated in STZ-treated 5XFAD mice. Our result is consistent with a recent report showing that expression levels of full-length APP are increased by STZ treatments in the absence of changes in APP mRNA levels in APP/PS1 transgenic mice [23]. Therefore, it seems likely that post-transcriptional upregulation of both BACE1 and its substrate APP may work cooperatively, leading to significant acceleration of β-amyloidogenesis in brains of insulin-deficient diabetic AD mice.

Figure 4. Effects of STZ-induced insulin deficiency on neprilysin and IDE levels in 5XFAD mice. (A) Western blot analysis of hemibrain lysates from vehicle- and STZ-treated 5XFAD mice. (B) Immunoreactive bands for neprilysin and IDE were quantified and expressed as the percentage of vehicle-treated 5XFAD levels (n = 4-7 mice per group). There was no difference in neprilysin or IDE levels between STZ- and vehicle-treated 5XFAD mice. All data are presented as mean ± SEM. doi:10.1371/journal.pone.0032792.g004
In contrast, STZ treatments did not affect levels of the \( \beta \)-degrading enzymes such as neprilysin and IDE in 5XFAD mouse brains. Our present results as well as others [23] indicate that the facilitation of \( \beta \)-production, which is accompanied by increases in the intermittent \( \beta \)-cleaved C-terminal fragment C99 resulting from elevated BACE1 and APP expression, may account for the exacerbation of \( \beta \) accumulation in brains of STZ-induced diabetic AD transgenic mice. These findings are in contrast with a report showing that STZ–induced insulin deficiency caused reductions in IDE without affecting C99 levels in APP mice, suggesting that diabetes-associated exaggeration of \( \beta \)-amyloidosis may be a result of reduced \( \beta \) degradation rather than increased \( \beta \) generation [21]. This discrepancy may arise from differences in transgenic AD mouse models used for the experiments and the age tested or the extent to which STZ treatments reduce cerebral insulin levels. Further study will be required to address the relative contribution of increased generation and/or reduced degradation of \( \beta \) to the enhanced \( \beta \)-amyloidosis in diabetic AD mice, with special focus on the relationship to alterations in insulin signaling pathways.

In conclusion, the results presented here demonstrate that STZ-induced insulin-deficient diabetes exacerbates \( \beta \) accumulation by elevating expression levels of the \( \beta \)-secretase enzyme BACE1 and its substrate APP in the 5XFAD mouse model of AD. BACE1 elevations in diabetic 5XFAD mouse brains seem to be associated with transcriptional upregulation through the PERK-eIF2\( \alpha \)-phosphorylation pathway rather than transcriptional mechanisms or changes in the GGA3-dependent lysosomal degradation. Our data support the hypothesis that deficient insulin signaling may represent a critical contributing factor in the acceleration of \( \beta \)-amyloidogenesis during the progression of sporadic AD and thus may be an important therapeutic target in AD treatments.

**Materials and Methods**

**Animals**

We used 5XFAD transgenic mice (Tg6799 line) that co-overexpress FAD mutant forms of human APP (the Swedish mutation: K670N, M671I; the Florida mutation: I716V; the London mutation: V717I) and PS1 (M146I; L286V) transgenes under transcriptional control of the neuron-specific mouse Thy-1 promoter [24–26]. 5XFAD lines (B6/SJL genetic background) were maintained by crossing hemizygous transgenic mice with B6/SJL F1 breeders (Taconic, Hudson, NY, USA). 5XFAD transgenic mice used were hemizygotes with respect to the transgene and non-transgenic wild-type littermate mice served as controls. Genotyping was performed by PCR analysis of tail DNA, as described [24]. Procedures were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Nathan Kline Institute Animal Care and Use Committee (Assignment number: AP2008-260).

**Induction of insulin-deficient diabetes**

5XFAD and wild-type control mice at 1.5 months of age were fasted overnight and received an intraperitoneal injection of streptozotocin (STZ, Sigma-ALDRICH, St Louis, MO, USA) at 90 mg/kg or saline vehicle once daily for two consecutive days. The mice were sacrificed at 4 months of age and brain samples were collected for analysis.

**Immunoblot analysis**

Hemibrain samples were taken from the mice under deep isoflurane anesthesia and were snap-frozen for biochemical assays. For western blot analysis, each sample was homogenized in 5 volumes of modified RIPA buffer containing 150 mM NaCl, 50 mM Tris HCl (pH 8.0), 1 mM EDTA, 1% IGEPAL, 0.5% sodium deoxycholate, 0.1% SDS and protease/phosphatase inhibitor cocktail (Calbiochem, La Jolla, CA, USA), and centrifuged at 10,000 g for 10 min to remove any insoluble material. Protein concentrations were determined by a BCA protein assay kit (Pierce, Rockford, IL, USA), and 20–50 µg of protein was run on 4–12% NuPAGE gels (Invitrogen, Carlsbad, CA, USA) and transferred to nitrocellulose membranes. After blocking, membranes were probed with anti-insulin (1:500, sc-9168, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-insulin receptor (1:2,000, MAB6555, Millipore, Billerica, MA, USA), anti-BACE1 (1:1,000, MAB3308, Millipore), anti-AD-AM10 (1:2,500, 422751, Calbiochem), anti-PS1 (1:1,000, 529591, Calbiochem), an antibody that recognizes C-terminal epitope in APP (1:1,000, C1/6, kindly provided by Dr. Paul Mathews, Nathan Kline Institute) to detect full-length APP/C-terminal fragments, anti-sAPP\( \alpha \) (1:500, 11088, Immuno-Biological Laboratories, Minneapolis, MN, USA), anti-phospho-eIF2\( \alpha \) (Ser51) (1:1,000, #33367, Cell Signaling Technology, Danvers, MA, USA), anti-eIF2\( \alpha \) (1:2,000, #9272, Cell Signaling Technology), anti-phospho-PERK (Ser723) (1:500, #649401, BioLegend, San Diego, CA, USA), anti-cleaved caspase-3 (Asp175) (1:1,000, #9661, Cell Signaling Technology), anti-GGA3 (1:1,500, #4167, Cell Signaling Technology), anti-neprilysin 1:2,000, ab9511, Abcam, Cambridge, MA, USA), anti-IDE (1:2,000, PC730, Millipore) or anti-\( \beta \)-actin (1:15,000, AC-15, Sigma-Aldrich). They were then incubated with horseradish peroxidase-conjugated secondary IgG. Immunoblot signals were visualized by an ECL chemiluminescence substrate reagent kit (Pierce) and quantified by densitometric scanning and image analysis using Quantity One software (Bio-Rad Laboratories, Hercules, CA, USA).

**ELISAs of \( \beta \)40 and \( \beta \)42**

Sandwich \( \beta \) ELISAs were performed as described previously [30,31,53]. Briefly, each hemibrain sample was extracted in 8X cold 5 M guanidine HCl plus 50 mM Tris HCl (pH 8.0) buffer, and centrifuged at 20,000 g for 1 h at 4°C to remove insoluble material. Final guanidine HCl concentrations were below 0.1 M. Protein concentrations were determined by a BCA kit (Pierce). To quantitate total levels of cerebral \( \beta \)40 and \( \beta \)42, supernatant fractions were analyzed by a well-established human \( \beta \)40 and \( \beta \)42 ELISA kits (KHB3481 and KHB3441, Invitrogen), respectively, according to the protocol of the manufacturer. Optical densities at 450 nm of each well were read on a VersaMax tunable microplate reader (Molecular Devices, Sunnyvale, CA, USA), and sample \( \beta \)40 and \( \beta \)42 concentrations were determined by comparison with the respective standard curves. \( \beta \)40 and \( \beta \)42 concentration values were normalized to total brain protein concentrations and expressed as the percentage of vehicle controls.

**Real-time qPCR**

qPCR was performed in triplicate on frozen hemibrain samples as described previously [52,54,55]. TaqMan qPCR primers were utilized for mouse BACE1 mRNA (Mm00478671_m1, Applied Biosystems, Foster City, CA, USA) and the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Mm99999 9151_g1, Applied Biosystems). Samples were assayed on a real-time qPCR cycler (7900HT, Applied Biosystems) in 96-well optical plates covered with optical adhesive film. Standard curves and cycle threshold were generated using standards obtained from total
mouse brain RNA. The delta delta cycle threshold (ddCT) method was employed to determine relative gene level differences between STZ- and vehicle-treated 5XFAD mice with GAPDH qPCR products used as a control, and expression levels were presented as the percentage of vehicle controls. Negative controls consisted of the reaction mixture without input RNA.

Statistical analysis

Significant differences between groups were determined by a one-way ANOVA and post-hoc Fisher’s LSD tests were performed when appropriate. Data were presented as mean ± SEM and the level of significance was set for p value less than 0.05.

Author Contributions

Conceived and designed the experiments: LD MO. Performed the experiments: LD MJ. Analyzed the data: LD MJA SDG MO. Wrote the paper: LD MO.

References

1. Hardy JA, Higgins GA (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 256: 184–185.
2. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297: 153–156.
3. Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, et al. (2011) Diabetes mellitus and Alzheimer’s disease: shared pathology and treatment? Br J Clin Pharmacol 71: 10–18.
4. Holscher C (2011) Diabetes as a risk factor for Alzheimer’s disease: insulin signaling impairment in the brain as an alternative model of Alzheimer’s disease. Biochem Soc Trans 39: 891–897.
5. Ohno M (2011) A common pathogenic mechanism linking type-2 diabetes and Alzheimer’s disease: evidence from animal models. J Clin Neurol 7: 10–18.
6. Dodel R, Blum-Degen D, Bernstein HG, Engelberger S, Humrich J, et al. (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease. J Neurol Neurosurg Psychiatry 65: 432–438.
7. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2011) Deficient brain insulin signaling pathway in Alzheimer’s disease and diabetes. J Pathol 225: 54–62.
8. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, et al. (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease–is this type 3 diabetes? J Alzheimers Dis 7: 63–80.
9. Rivera E, Goldlin A, Fulmer N, Tavares R, Wands JR, et al. (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholine. J Alzheimers Dis 8: 247–268.
10. Menon R, Farina C (2011) Shared molecular and functional frameworks among five complex human disorders: a comparative study on interactomes linked to susceptibility genes. PLoS One 6: e16071.
11. de la Monte SM, Wands JR (2008) Alzheimer’s disease is type 3 diabetes–evidence reviewed. J Diabetes Sci Technol 2: 1101–1113.
12. Gugger M, McClain PL, Mcrinnut R, Gaul VA, Holscher C (2012) Val(8)GLP-1 triggers the insulin signaling pathway in peripheral tissues. Mol Neurodegener 5: 46.
13. De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, et al. (2009) Protection of synapses against Alzheimer-linked toxins: insulin signaling-mediated transduction cascades common to the insulin receptor pathway. J Biol Chem 284: 112–116.
14. Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, et al. (2010) GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease. J Alzheimers Dis 19: 1205–1219.
15. Mehta T, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease. J Cereb Blood Flow Metab 22: 24108–24119.
16. Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O (2012) Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer’s disease. Neurobiol Aging 33: 196.e29–196.e40.
17. Devi L, Ohno M (2010) Genetic reductions of β-site amyloid precursor protein-cleaving enzyme 1 and amyloid-β ameliorate impairment of conditioned taste aversion memory in 5XFAD Alzheimer’s disease mouse models. Eur J Neurosci 31: 110–118.
18. Devi L, Ohno M (2010) Phospho-eIF2β level is important for determining abilities of BACE1 reduction to rescue cholinergic neurodegeneration and memory deficits in 5XFAD mice. PLoS One 5: e12974.
19. Chang RC, Wong AK, Ng HK, Hugan J (2002) Phosphorylation of eukaryotic initiation factor-2α (eIF2α) is associated with neuronal degeneration in Alzheimer’s disease. Neuroreport 13: 2429–2432.
20. O’Connor T, Sadre KR, Maas E, Velliquette RA, Zhao J, et al. (2008) Phosphorylation of the translation initiation factor eIF2α increases BACE1 levels and promotes amyloidogenesis. Neuron 60: 988–1009.
21. Tesco G, Koh YH, Kang EL, Cameron AN, Das S, et al. (2007) Depletion of GGA3 stabilizes BACE and enhances β-secretase activity. Neuron 54: 721–737.
22. Sarazjavi T, Haaspano A, Vaswathanol J, Makinen P, Laitinen M, et al. (2009) Down-regulation of seladin1 increases BACE1 levels and activity through enhanced GGA3 depletion during apoptosis. J Biol Chem 284: 34433–34443.
23. Kang EL, Cameron AN, Piazza F, Walker KR, Tesco G (2010) Ubitquitin regulates GGA3-mediated degradation of BACE1. J Biol Chem 285: 24108–24119.
24. Santos A, Rasche S, Barakat A, Bellingham SA, Ho M, et al. (2011) Decreased expression of GGA3 protein in Alzheimer’s disease frontal cortex and increased distribution of BACE with the amyloid precursor protein. Neurobiol Dis 43: 147–163.
25. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, et al. (2001) Metabolic regulation of brain Aβ by neprilysin. Science 292: 1550–1552.
26. Qi WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, et al. (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid-β protein by degradation. J Biol Chem 273: 32730–32738.
27. Ke YD, Deleuze F, Gladbach A, Gotz J, Inner JM (2009) Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer’s disease. PLoS One 4: e7917.
28. Sullivan JM, Aloisi SS, Hikade KR, Buhl NJ, Rofko JA, et al. (1999) Insulin induces dephosphorylation of eukaryotic initiation factor 2α and restores protein synthesis in vulnerable hippocampal neurons after transient brain ischemia. J Cereb Blood Flow Metab 19: 1010–1019.
29. Hu C, Cong XD, Dai HY, Zhang Y, Zhang GL, et al. (2011) Argirein alleviates impaired memory and synaptic plasticity in the 5XFAD mouse model of Alzheimer’s disease. Neuropharmacology 59: 1381–1389.
30. Rossner S, Sastre M, Bourne K, Lichtenthaler SF (2006) Transcriptional and translational regulation of BACE1 expression-implications for Alzheimer’s disease. Prog Neurobiol 79: 95–111.
46. Li R, Lindholm K, Yang LB, Yue X, Citron M, et al. (2004) Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer’s disease patients. Proc Natl Acad Sci USA 101: 3632–3637.

47. Coulson DT, Beyer N, Quinn JG, Brockbank S, Hellemans J, et al. (2010) BACE1 mRNA expression in Alzheimer’s disease postmortem brain tissue. J Alzheimers Dis 22: 1111–1122.

48. Matsui T, Ingelsson M, Fukuimoto H, Ramasamy K, Kowa H, et al. (2007) Expression of APP pathway mRNAs and proteins in Alzheimer’s disease. Brain Res 1161: 116–123.

49. Holsinger RM, McLean CA, Beyreuther K, Masters C, Evin G (2002) Increased expression of the amyloid precursor β-secretase in Alzheimer’s disease. Ann Neurol 51: 783–786.

50. Borghi R, Patriarca S, Traverso N, Piccini A, Storace D, et al. (2007) The increased activity of BACE1 correlates with oxidative stress in Alzheimer’s disease. Neurobiol Aging 28: 1099–1014.

51. Preece P, Virley DJ, Costandi M, Coombes R, Moss SJ, et al. (2003) β-Secretase (BACE) and GSK-3 mRNA levels in Alzheimer’s disease. Brain Res Mol Brain Res 116: 155–158.

52. Devi L, Aldred MJ, Ginsberg SD, Ohno M (2010) Sex- and brain region-specific acceleration of β-amyloidogenesis following behavioral stress in a mouse model of Alzheimer’s disease. Mol Brain 3: 34.

53. Kimura R, Devi L, Ohno M (2010) Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer’s disease transgenic mice. J Neurochem 115: 248–261.

54. Aldred MJ, Che S, Ginsberg SD (2008) Terminal Continuation (TC) RNA amplification enables expression profiling using minute RNA input obtained from mouse brain. Int J Mol Sci 9: 2091–2104.

55. Ginsberg SD (2008) Transcriptional profiling of small samples in the central nervous system. Methods Mol Biol 439: 147–158.